Insider Buying: Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Buys 382,352 Shares

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Global Strategic Fund Venbio acquired 382,352 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, with a total value of $6,499,984.00. Following the transaction, the insider owned 4,181,367 shares in the company, valued at approximately $71,083,239. The trade was a 10.06% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Attovia Therapeutics Price Performance

NASDAQ ATTO traded down $0.33 during trading hours on Monday, reaching $19.84. The company’s stock had a trading volume of 376,495 shares, compared to its average volume of 342,531. Attovia Therapeutics, Inc. has a 52 week low of $18.50 and a 52 week high of $22.79.

Institutional Trading of Attovia Therapeutics

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. increased its position in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.